GURUFOCUS.COM » STOCK LIST » Energy » Oil & Gas » Core Laboratories Inc (NYSE:CLB) » Definitions » Debt-to-EBITDA
中文

Core Laboratories (Core Laboratories) Debt-to-EBITDA

: 5.59 (As of Mar. 2023)
View and export this data going back to 1995. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Core Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $11.1 Mil. Core Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $224.2 Mil. Core Laboratories's annualized EBITDA for the quarter that ended in Mar. 2023 was $42.1 Mil. Core Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 was 5.59.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Core Laboratories's Debt-to-EBITDA or its related term are showing as below:

CLB's Debt-to-EBITDA is not ranked *
in the Oil & Gas industry.
Industry Median: 1.73
* Ranked among companies with meaningful Debt-to-EBITDA only.

Core Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Core Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core Laboratories Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.05 3.20 -5.85 3.92 3.79

Core Laboratories Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.96 3.81 3.14 2.82 5.59

Competitive Comparison

For the Oil & Gas Equipment & Services subindustry, Core Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Core Laboratories Debt-to-EBITDA Distribution

For the Oil & Gas industry and Energy sector, Core Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Core Laboratories's Debt-to-EBITDA falls into.



Core Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Core Laboratories's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11.699 + 210.691) / 58.685
=3.79

Core Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11.073 + 224.233) / 42.1
=5.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2023) EBITDA data.


Core Laboratories  (NYSE:CLB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Core Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Core Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Core Laboratories (Core Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
6316 Windfern Road, Houston, TX, USA, 77040
Core Laboratories is the premier provider of reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
Executives
Katherine Murray director 6316 WINDFERN ROAD, HOUSTON TX 77040
Mark Damian Tattoli officer: SVP, Gen Counsel & Secretary C/O CORE LABORATORIES LP, 6316 WINDFERN ROAD, HOUSTON TX 77040
Kwaku Temeng director C/O CORE LABORATORIES LP, 2216 SHERIDAN STREET, HOUSTON TX 77002
Gwendolyn Schreffler officer: SVP C/O CORE LABORATORIES LP, 6316 WINDFERN ROAD, HOUSTON TX 77040
Harvey Robert Klingensmith director P.O. BOX 131144, HOUSTON TX 77219-1114
Van Dijken Eeuwijk Monique director P.O. BOX 129, BILTHOVEN P7 3720 AC
Jan Willem Sodderland director DUINDISTEL 89, NOORDWIJK P7 2202 DE
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Lawrence Bruno officer: President 6316 WINDFERN ROAD, HOUSTON TX 77040
Mark F Elvig officer: VP, Counsel & Secretary 6316 WINDFERN, HOUSTON TX 77040
Gregory Barry Barnett director 853 MILWAUKEE STREET, DENVER CO 80206
Kevin Daniels officer: CAO & Treasurer 6316 WINDFERN ROAD, HOUSTON TX 77040
Michael Straughen director 68 RUBISLAW DEN NORTH, ABERDEEN X0 AB15 4AN
Martha Z. Carnes director 6316 WINDFERN ROAD, HOUSTON TX 77040